Bio-Techne Corp (NASDAQ:TECH)
| 93.31 BATS BZX Real-Time Price |  -0.14 / -0.15%Today’s Change | 82.51 Today|||52-Week Range 97.15 | +0.98% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $3.5B |
Company Description
Bio-Techne Corp. is engaged in the development, manufacture and sale of biotechnology products and hematology calibrators and controls. The company operates through two segments: Biotechnology and Hematology. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, including proteins such as cytokines and related reagents, to the biotechnology research community. The Hematology segment develops and manufactures hematology controls and calibrators for sale world-wide. The company was founded on July 17, 1981 and is headquartered in Minneapolis, MN.
Contact Information
Bio-Techne Corp. 614 McKinley Place NE Minneapolis Minnesota 55413-2610 |
Employees
Shareholders
| Mutual fund holders | 55.03% |
| Other institutional | 38.97% |
| Individual stakeholders | 0.01% |
Top Executives
| Charles R. Kummeth | President & Chief Executive Officer |
| James T. Hippel | Chief Financial Officer |
| J. Fernando Bazan | Chief Technology Officer |
| Brenda S. Furlow | Senior Vice President & General Counsel |
| Marcel Veronneau | Vice President-Clinical Controls |
.